Literature DB >> 33355598

Clinical Decision-making About Neoadjuvant Nivolumab Plus Ipilimumab.

Manuel David Gil-Sierra1,2, Marina Sánchez-Hidalgo1, Catalina Alarcón de la Lastra-Romero1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33355598     DOI: 10.1001/jamaoncol.2020.6989

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN: 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  1 in total

Review 1.  Clinical and pharmacoeconomic impact of subgroup analysis in onco-hematological patients.

Authors:  Manuel David Gil-Sierra; Maria Del Pilar Briceño-Casado; Marina Sánchez-Hidalgo
Journal:  Support Care Cancer       Date:  2022-01-13       Impact factor: 3.359

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.